Cover Image

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review

Objective: The objective of this study is to systematically review the economic evaluations of dapagliflozin in the treatment of patients with heart failure (HF) and describe their general and methodological features.Methods: This systematic review followed the PRISMA guidelines. MEDLINE/PubMed, Web...

Full description

Saved in:

Bibliographic Details
Main Authors:	Meiyu Wu (Author), Shuxia Qin (Author), Liting Wang (Author), Chongqing Tan (Author), Ye Peng (Author), Xiaohui Zeng (Author), Xia Luo (Author), Lidan Yi (Author), Xiaomin Wan (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
by: Meiyu Wu, et al.
Published: (2022)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
by: Tan Chongqing, et al.
Published: (2021)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
by: Ye Peng, et al.
Published: (2022)

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study
by: Shuxia Qin, et al.
Published: (2022)

Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis
by: Chongqing Tan, et al.
Published: (2023)

First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis
by: Qiao Liu, et al.
Published: (2021)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
by: Qiao Liu, et al.
Published: (2022)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
by: Xia Luo, et al.
Published: (2022)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma
by: Haixia Zhang, et al.
Published: (2022)

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China
by: Kehui Meng, et al.
Published: (2024)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
by: Dongchu Zhou, et al.
Published: (2022)

Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis
by: Xiaohui Zeng, et al.
Published: (2022)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China
by: Liu Qiao, et al.
Published: (2021)

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
by: Gupta M, et al.
Published: (2021)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
by: Erik Håkansson, et al.
Published: (2021)

Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models
by: Huayang Li, et al.
Published: (2021)

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
by: Ahmed E. Ali, et al.
Published: (2023)

Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure
by: Xuefeng Chen, et al.
Published: (2022)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
by: Xingyun Hou, et al.
Published: (2019)

Compound Danshen dripping pills prevent early diabetic retinopathy: roles of vascular protection and neuroprotection
by: Xiaoyu Xu, et al.
Published: (2024)

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
by: Ronen Arbel, et al.
Published: (2024)

Quantitative effects of sodium-glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022)

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024)

Safety of dapagliflozin initiation in acute decompensated heart failure patients with reduced left ventricular ejection fraction
by: Anastasiya E. Poskakalova, et al.
Published: (2023)

Role of necroptosis and immune infiltration in preeclampsia: novel insights from bioinformatics analyses
by: Lidan He, et al.
Published: (2023)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023)

Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022)

Corrigendum: Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China
by: Jia Liu, et al.
Published: (2022)

The experience of nurses to reduce implicit rationing of nursing care: a phenomenological study
by: Hui Qin Li, et al.
Published: (2023)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
by: Xia Luo, et al.
Published: (2022)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
by: Edgardo Kaplinsky
Published: (2020)

Performance of PRISM III, PELOD-2, and P-MODS Scores in Two Pediatric Intensive Care Units in China
by: Lidan Zhang, et al.
Published: (2021)

High-Salt Attenuates the Efficacy of Dapagliflozin in Tubular Protection by Impairing Fatty Acid Metabolism in Diabetic Kidney Disease
by: Meina Zou, et al.
Published: (2021)

Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
by: Yao Wu, et al.
Published: (2018)

Serum levels of melatonin may contribute to the pathogenesis of heart failure in children with median age of 1 year
by: Yao Wu, et al.
Published: (2018)

Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis
by: Weichen Zhang, et al.
Published: (2024)

Discovery and antitumor evaluation of novel inhibitors of spermine oxidase
by: Lidan Sun, et al.
Published: (2019)

Clinical and economic analysis of using dapagliflozin in patients with chronic kidney disease in the Russian Federation
by: Sergey V. Nedogoda, et al.
Published: (2021)

Blood lead level is associated with non-alcoholic fatty liver disease in the Yangtze River Delta region of China in the context of rapid urbanization
by: Hualing Zhai, et al.
Published: (2017)